Sandrine Aspeslagh

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Three-year analysis of the Belgian multidisciplinary immunotoxicity (BITOX) board: organization, feasibility, and results.

Three-year analysis of the Belgian multidisciplinary immunotoxicity (BITOX) board: organization, feasibility, and results.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.

Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.

Journal: Frontiers in immunology

Published: January 22, 2026

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer.

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer.

Journal: ESMO open

Published: October 17, 2025

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer.

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer.

Journal: ESMO open

Published: October 17, 2025

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Journal: Acta oncologica (Stockholm, Sweden)

Published: May 15, 2025

Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

Journal: Cancer immunology, immunotherapy : CII

Published: December 31, 2024

Acquired hemophilia due to immune checkpoint inhibitors: a case series introducing emicizumab treatment.

Acquired hemophilia due to immune checkpoint inhibitors: a case series introducing emicizumab treatment.

Journal: The oncologist

Published: December 02, 2024

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes.

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes.

Journal: RMD open

Published: September 23, 2024

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.

Journal: Gynecologic oncology

Published: August 09, 2024

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 14, 2024

Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies.

Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 11, 2024

Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors: A case series and systematic literature review.

Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors: A case series and systematic literature review.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: April 13, 2023

Showing 1-12 of 89

Last Updated: 09/26/2026